Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; macrogol 8000; purified talc; iron oxide red; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; peg-40 hydrogenated castor oil; hypromellose; sodium starch glycollate; methacrylic acid copolymer; maize starch; simethicone; sorbic acid; steareth-2 - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: macrogol 8000; iron oxide yellow; peg-40 hydrogenated castor oil; acrylates copolymer; maize starch; sodium starch glycollate; purified talc; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; magnesium stearate; povidone; lactose monohydrate; titanium dioxide; simethicone; sorbic acid; steareth-2 - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 50 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 25 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 12.5 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac potassium, quantity: 50 mg - tablet, sugar coated - excipient ingredients: colloidal anhydrous silica; calcium phosphate; magnesium stearate; maize starch; povidone; sodium starch glycollate; microcrystalline cellulose; iron oxide red; macrogol 8000; sucrose; purified talc; titanium dioxide - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 100 mg - suppository, moulded - excipient ingredients: - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 1 mg/ml;   - eye drops, solution - 300 mcg/0.3ml - active: diclofenac sodium 1 mg/ml   excipient: boric acid polyoxyl 35 castor oil trometamol water for injection - voltaren ophtha eye drops are indicated for: · post-operative inflammation in cataract surgery and other surgical interventions. · prevention of cystoid macular oedema after cataract extraction with lens implantation. · post-traumatic inflammation in non-penetrating wounds. · inhibition of miosis in cataract surgery. · relief of pain and photophobia. · non-infected inflammatory conditions of the anterior segment of the eye.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 1 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; disodium edetate; hydroxypropylbetadex; hydrochloric acid; propylene glycol; trometamol; tyloxapol; water for injections - post-operative inflammation in cataract surgery and other surgical interventions.

Spojené státy - angličtina - NLM (National Library of Medicine)

rebel distributors corp - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see   warnings and precautions (5.1 )] . the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with other nsaids,